Literature DB >> 20814894

Drug therapy: rifaximin.

Jasmohan S Bajaj1, Oliviero Riggio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20814894     DOI： 10.1002/hep.23866

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  18 in total

1.  Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; Puneeta Tandon; Florence Wong; Patrick S Kamath; Scott W Biggins; Guadalupe Garcia-Tsao; Jennifer Lai; Michael B Fallon; Paul J Thuluvath; Hugo E Vargas; Benedict Maliakkal; Ram M Subramanian; Leroy R Thacker; K Rajender Reddy
Journal:  Aliment Pharmacol Ther       Date:  2019-04-29       Impact factor: 8.171

2.  Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis.

Authors:  Jasmohan S Bajaj; Steven D Pinkerton; Arun J Sanyal; Douglas M Heuman
Journal:  Hepatology       Date:  2012-04       Impact factor: 17.425

Review 3.  Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.

Authors:  Kavish R Patidar; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-09       Impact factor: 11.382

4.  Advantageous Solubility-Permeability Interplay When Using Amorphous Solid Dispersion (ASD) Formulation for the BCS Class IV P-gp Substrate Rifaximin: Simultaneous Increase of Both the Solubility and the Permeability.

Authors:  Avital Beig; Noa Fine-Shamir; David Lindley; Jonathan M Miller; Arik Dahan
Journal:  AAPS J       Date:  2017-02-15       Impact factor: 4.009

5.  Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice.

Authors:  Qiang Zhu; Li Zou; Kumaravelu Jagavelu; Douglas A Simonetto; Robert C Huebert; Zhi-Dong Jiang; Herbert L DuPont; Vijay H Shah
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

Review 6.  Antibiotics for the treatment of hepatic encephalopathy.

Authors:  Kavish R Patidar; Jasmohan S Bajaj
Journal:  Metab Brain Dis       Date:  2013-02-08       Impact factor: 3.584

7.  Rifaximin therapy and hepatic encephalopathy: Pros and cons.

Authors:  Angelo Zullo; Cesare Hassan; Lorenzo Ridola; Roberto Lorenzetti; Salvatore Ma Campo; Oliviero Riggio
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-08-06

Review 8.  Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.

Authors:  Francesca Romana Ponziani; Viviana Gerardi; Silvia Pecere; Francesca D'Aversa; Loris Lopetuso; Maria Assunta Zocco; Maurizio Pompili; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

Review 9.  Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.

Authors:  Min Seok Cho; Sang Yeol Kim; Ki Tae Suk; Byung-Yong Kim
Journal:  J Microbiol       Date:  2018-10-25       Impact factor: 3.422

10.  Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind study.

Authors:  Fernando Gomes Romeiro; Fabio da Silva Yamashiro; Madileine Francely Américo; Luciana Aparecida Corá; Giovanni Faria Silva; José Ricardo de Arruda Miranda; Carlos Antonio Caramori
Journal:  BMC Gastroenterol       Date:  2013-01-16       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.